Workflow
AbbVie Stock Falls As Company Warns of Continued Humira Sales Slump
AbbVieAbbVie(US:ABBV) Investopedia·2024-04-27 03:25

AbbVie公司业绩 - AbbVie警告称，其旗舰关节炎药物Humira的销售将继续输给生物类似药物[1] - 尽管Humira销售下降，但AbbVie在该季度超过了盈利和收入预测，并提高了全年指导[1] - AbbVie的股价在周五晚间交易中下跌了近5%[1]